USPTO trademark

PHENO LOCK

RegisteredUSPTOWord markClass 1Class 5Class 40

"PHENO LOCK" is a word mark owned by Quell Therapeutics Limited, filed at the USPTO on October 10, 2022. It is registered and covers classes 1, 5 and 40.

View Quell Therapeutics Limited portfolioGet this data via the API
Official USPTO record
PHENO LOCK trademark as filed
As filed with the USPTO
Status
Registered
Since October 24, 2023
Filed
October 10, 2022
Registered
October 24, 2023
Priority date
April 11, 2022
Claimed from United Kingdom
Application no.
97626317
Registration no.
7201861
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
3 classes
Ownership

Who owns PHENO LOCK

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Quell Therapeutics Limited

London, United Kingdom

6 trademarks in the portfolioView company

Representative

Carlynn Ferguson

Iphorgan

Goods and services

What the mark covers

The products and services PHENO LOCK is filed for, grouped by Nice class.

  • Class 1: Chemical and biological preparations for use in science and industry; chemical and biological preparations for non-medical purposes; Chemical and biological preparations for genetically modifying human and animal cells for non-medical purposes; reagents for use in the genetic modification of human and animal cells for scientific or medical research use; human and animal cells and parts in the nature of stem cells thereof for scientific and research purposes; T cells for scientific and research purposes; regulatory T cells for scientific and research purposes; preparations of blood or cells extracted from humans and animals for scientific and research purposes; immunological agents and preparations for non-medical purposes; chimeric antigen receptors and preparations thereof for scientific and research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use for use in science and industry; nucleic acids for laboratory use; nucleic recombinant acids; synthetic deoxyribonucleic acids for scientific purposes; viral vectors for use in science and industry; nucleic acid vectors for use in science and industry

  • Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely, for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical, medical and veterinary preparations for diagnostic, therapeutic and prophylactic purposes, namely, for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; human and animal cells and parts, namely, stem cells thereof for medical and veterinary purposes; T cells for medical and veterinary purposes; regulatory T cells for medical and veterinary purposes; preparations of blood or cells extracted from humans and animals which have been adapted for therapeutic purposes; pharmaceutical, medical and clinical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; immunological agents and preparations for medical purposes; pharmaceutical preparations for therapies to modulate the immune system; pharmaceutical preparations for therapies for autoimmune conditions and immunological disorders; chimeric antigen receptors and therapeutic preparations for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; [ Colostral antibodies for diagnostic, medical, therapeutic and prophylactic use, namely, for medical conditions caused by the immune system; ] pharmaceutical preparations for therapeutic delivery of nucleic acids; viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection

  • Pharmaceutical manufacturing and processing; biological, biotechnological and biopharmaceutical manufacturing and manufacturing processing; manufacturing processing of biological tissue, blood, cell and genetic material; viral vector production, namely manufacture; gene therapy production, namely manufacture; custom manufacture of pharmaceutical and biological formulations and products; processing and modification of human and animal cells in the custom manufacture of pharmaceutical and biological formulations and products

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Teas change of correspondence received
  2. Teas change of domestic representatives address
  3. Attorney/dom.rep.revoked and/or appointed
  4. Teas revoke/app/change addr of atty/dom rep received
  5. Notice of updated registration confirmation emailed
  6. Amendment under section 7 - processed
  7. Teas section 7 request received
  8. Case assigned to post registration paralegal
  9. Teas section 7 request received
  10. Notice of registration confirmation emailed

10 earlier steps on the official record.

FAQ

About PHENO LOCK

Who owns the trademark "PHENO LOCK"?

The USPTO trademark "PHENO LOCK" (application 97626317) is owned by Quell Therapeutics Limited.

What is the status of "PHENO LOCK"?

Its status at the USPTO is: registered.

When was "PHENO LOCK" registered?

It was registered on October 24, 2023.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull PHENO LOCK and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d2b02-3942-772e-ad59-1cecf57e0c3d
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d2b02-3942-772e-ad59-1cecf57e0c3d",
  "object": "trademark",
  "mark_text": "PHENO LOCK",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "US",
  "application_number": "97626317",
  "filing_date": "2022-10-10",
  "nice_classes": [
    1,
    5,
    40
  ],
  "owners": [
    {
      "name": "Quell Therapeutics Limited",
      "entity_id": "ent_019eb713-28ed-72ad-82d5-ad53e70b1c35"
    }
  ]
}